Holen Sie sich die Stockscreener-App
0.9165
4.17%
0.0286
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt SCYX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$0.8879
Offen:
$0.88
24-Stunden-Volumen:
487.68K
Relative Volume:
0.87
Marktkapitalisierung:
$40.93M
Einnahmen:
$20.60M
Nettoeinkommen (Verlust:
$-8.61M
KGV:
-6.6361
EPS:
-0.1381
Netto-Cashflow:
$-5.28M
1W Leistung:
+17.12%
1M Leistung:
+15.61%
6M Leistung:
+17.33%
1J Leistung:
+10.11%
1-Tages-Spanne:
$0.88
$0.9498
1-Wochen-Bereich:
$0.762
$0.9498
52-Wochen-Spanne:
$0.565
$1.31
Scynexis Inc Stock (SCYX) Company Profile
Firmenname
Scynexis Inc
Sektor
Telefon
201-884-5485
Adresse
1 EVERTRUST PLAZA, JERSEY CITY, NJ
Compare SCYX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SCYX
Scynexis Inc
|
0.9165 | 39.66M | 20.60M | -8.61M | -5.28M | -0.1381 |
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.16 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.67 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
554.53 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Scynexis Inc Stock (SCYX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-22 | Eingeleitet | Guggenheim | Buy |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-11 | Hochstufung | Needham | Hold → Buy |
| 2018-06-27 | Eingeleitet | Maxim Group | Buy |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-10 | Eingeleitet | ROTH Capital | Buy |
| 2017-05-09 | Herabstufung | Needham | Buy → Hold |
| 2017-03-03 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-07 | Hochstufung | WBB Securities | Buy → Strong Buy |
| 2016-10-03 | Fortgesetzt | Brean Capital | Buy |
| 2016-08-17 | Eingeleitet | Guggenheim | Buy |
| 2016-08-09 | Bestätigt | Needham | Buy |
| 2016-08-09 | Hochstufung | WBB Securities | Speculative Buy → Buy |
| 2016-03-28 | Eingeleitet | Brean Capital | Buy |
| 2015-12-29 | Eingeleitet | WBB Securities | Speculative Buy |
| 2015-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-06-10 | Eingeleitet | Needham | Buy |
| 2014-05-29 | Eingeleitet | Canaccord Genuity | Buy |
| 2014-05-29 | Eingeleitet | RBC Capital Mkts | Outperform |
Alle ansehen
Scynexis Inc Aktie (SCYX) Neueste Nachrichten
Scynexis CEO Angulo Gonzalez buys $100k in shares By Investing.com - Investing.com Australia
Scynexis CEO Angulo Gonzalez buys $100k in shares - Investing.com
SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan
SCYNEXIS, Inc. (SCYX) stock price, news, quote and history - Yahoo Finance UK
SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD TherapeuticsSlideshow (NASDAQ:SCYX) 2026-04-01 - Seeking Alpha
SCYNEXIS raises $40 million in private placement financing By Investing.com - Investing.com South Africa
SCYNEXIS acquires SCY-770 for rare kidney disease treatment By Investing.com - Investing.com South Africa
SCYNEXIS Acquires SCY-770, Refocuses on Rare Kidney Disease - TipRanks
SCYX Should I Buy - Intellectia AI
SCYNEXIS (SCYX) extends cash runway to 2029 with $40M PIPE and SCY-770 ADPKD deal - Stock Titan
SCYNEXIS Acquires PXL-770 (SCY-770) to Advance Innovative ADPKD Therapy with Phase 2 Trial Planned for 2026 - Minichart
SCYNEXIS Announces $40 Million Private Placement to Fund SCY-770 Development for Rare Kidney Disease - Minichart
Why did SCYX stock jump 10% in pre-market today? - MSN
SCYNEXIS Acquires AMPK Program, Expands Rare Disease Pipeline - TipRanks
SCYNEXIS Raises $40 Million in Strategic Private Placement - TipRanks
SCYX to Acquire Poxel's PXL770, Targeting ADPKD Treatment Market - GuruFocus
SCYX: Acquisition of SCY-770 enables rapid entry into rare renal disease with strong clinical and commercial prospects - TradingView
Poxel Sells Kidney‑Disease Drug Candidate to Scynexis for Up to $196 Million - Contract Pharma
SCYNEXIS Acquires Novel AMPK Activator for Polycystic Kidney Disease - National Today
Scynexis (SCYX) Secures Acquisition of Innovative Kidney Disease Treatment - GuruFocus
SCYNEXIS Raises $40M in Private Placement - National Today
SCYNEXIS Inc Corporate Update Call Transcript - GuruFocus
SCYNEXIS Acquires Promising ADPKD Therapy PXL-770 - National Today
Scynexis (SCYX) Secures $40M Through Private Placement Agreement - GuruFocus
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease - marketscreener.com
Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market - Stocktwits
Press Release: Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Moomoo
Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - Business Wire
Scynexis (NASDAQ: SCYX) prices $40M equity private placement with warrants - Stock Titan
Scynexis Acquires Poxel's AMPK Activator Program, Paying $8M Upfront Plus Up To $188M Milestones - TradingView
SCYNEXIS raises $40 million in private placement financing - Investing.com
SCYNEXIS acquires SCY-770 for rare kidney disease treatment - Investing.com
Scynexis (NASDAQ: SCYX) buys SCY-770 kidney drug for $8M upfront - Stock Titan
SCYNEXIS Announces $40.0 Million Private Placement - The Manila Times
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) - The Manila Times
SCYX: Acquisition of SCY-770 targets ADPKD, expanding the rare disease portfolio with a novel therapy - TradingView
SCYNEXIS lands cash to fund rare disease drug work into mid-2029 - Stock Titan
Kidney disease drug with Phase 2 study due this year joins SCYNEXIS - Stock Titan
Scynexis Jumps on SCY-770 Deal — But Volume Tells a Cautious Story - Bitget
SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding - marketscreener.com
First Participants Dosed in Phase Trial of SCY-247, Building on Oral Formulation Success - Contagion Live
If You Invested $1,000 in Scynexis (SCYX) - Stock Titan
SCYNEXIS (NASDAQ:SCYX) Rating Lowered to “Hold” at Wall Street Zen - Defense World
Published on: 2026-03-22 14:13:05 - baoquankhu1.vn
EBIT per share of SCYNEXIS, Inc. – LSE:0L49 - TradingView
SCYNEXIS (SCYX) Price Target Decreased by 21.43% to 3.74 - MSN
SCYNEXIS, Inc. (SCYX) announces first participants dosed in phase 1 trial of SCY-247 antifungal therapy - MSN
SCYX SEC FilingsScynexis 10-K, 10-Q, 8-K Forms - Stock Titan
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Insider Monkey
Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - in.investing.com
Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Nigeria
Finanzdaten der Scynexis Inc-Aktie (SCYX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):